GO:0016024 CDP-diacylglycerol biosynthetic process: Lipid Intermediate Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0016024 describes the enzymatic formation of CDP-diacylglycerol (CDP-DAG), a central lipid intermediate linking phosphatidic acid to phosphatidylinositol and cardiolipin synthesis.
• The reaction is catalyzed by CDP-diacylglycerol synthases (CDS1, CDS2, and microbial homologs), which convert phosphatidic acid and CTP to CDP-DAG and pyrophosphate.
• CDP-DAG is a branchpoint metabolite: it is used for phosphatidylinositol synthesis at the endoplasmic reticulum and for cardiolipin synthesis in mitochondria.
• Loss of CDS1 impairs tumorigenic characteristics in nasopharyngeal carcinoma by modulating lipid metabolism, linking this pathway to cancer biology.
• Enzyme activity levels regulate phospholipid biosynthetic enzymes, indicating feedback control of the pathway.
• CRISPR knockout, point mutation, knock-in, and overexpression models enable causal dissection of CDP-DAG biosynthetic genes in health and disease.
Description
CDP-diacylglycerol biosynthetic process (GO:0016024) is the set of chemical reactions and pathways that produce CDP-1,2-diacylglycerol, a substance composed of diacylglycerol in glycosidic linkage with cytidine diphosphate. This lipid intermediate sits at a metabolic crossroads, because it is the activated donor for phosphatidylinositol synthesis and a precursor for mitochondrial cardiolipin. Researchers study GO:0016024 because its products and downstream lipids influence membrane biogenesis, organelle identity, and cell signaling. The pathway is conserved from microorganisms to mammals, with dedicated CDP-diacylglycerol synthase enzymes characterized in bacteria, yeast, and mammalian tissues. Beyond housekeeping lipid production, the pathway has emerged as a disease-relevant node: loss of CDS1 impairs the tumorigenic characteristics of nasopharyngeal carcinoma by modulating lipid metabolism. Because CDP-DAG synthesis is a branchpoint, its regulation affects the balance between phosphatidylinositol, cardiolipin, and other phospholipids. This article integrates the QuickGO definition with verified PubMed literature to summarize the mechanism, key genes, disease links, and experimental models for GO:0016024.
CDP-diacylglycerol biosynthetic process At A Glance
| GO ID | GO:0016024 |
|---|---|
| GO term | CDP-diacylglycerol biosynthetic process |
| Ontology | biological_process |
| Synonym | CDP-diacylglycerol anabolism; CDP-diacylglycerol biosynthesis; CDP-diacylglycerol formation; CDP-diacylglycerol synthesis |
| Major function | Synthesis of CDP-diacylglycerol, a key intermediate for phosphatidylinositol and cardiolipin production |
| Key enzymes | CDP-diacylglycerol synthases (CDS1, CDS2, and microbial homologs) |
| Substrates | Phosphatidic acid and CTP |
| Products | CDP-diacylglycerol and pyrophosphate |
| Subcellular locations | Endoplasmic reticulum and mitochondria |
What Is GO:0016024?
GO:0016024, CDP-diacylglycerol biosynthetic process, is defined as the chemical reactions and pathways resulting in the formation of CDP-diacylglycerol, CDP-1,2-diacylglycerol, a substance composed of diacylglycerol in glycosidic linkage with cytidine diphosphate. In simpler terms, it is the biosynthetic route that activates phosphatidic acid by coupling it to CTP, yielding the high-energy lipid intermediate CDP-DAG. This process is a biological_process in the Gene Ontology and is synonymous with CDP-diacylglycerol anabolism, biosynthesis, formation, and synthesis.
Why Is CDP-diacylglycerol biosynthetic process Important in Cell Biology?
GO:0016024 is important because CDP-diacylglycerol is a critical intermediate in lipid metabolism that connects phosphatidic acid to the synthesis of phosphatidylinositol and cardiolipin, thereby influencing membrane composition, organelle function, and cell signaling. The pathway is conserved across microorganisms and mammals, making it a tractable target for genetic and biochemical studies. Its dysregulation has been linked to cancer, as loss of CDS1 impairs tumorigenic characteristics in nasopharyngeal carcinoma by modulating lipid metabolism. Moreover, the level of CDP-diacylglycerol synthase activity regulates phospholipid biosynthetic enzymes, indicating that this pathway exerts feedback control over broader lipid homeostasis.
• Provides CDP-DAG, the activated lipid donor required for phosphatidylinositol synthesis at the endoplasmic reticulum.
• Supplies the precursor for cardiolipin synthesis in mitochondria, affecting mitochondrial membrane integrity.
• Acts as a branchpoint metabolite that balances phosphatidylinositol and cardiolipin production.
• Is conserved from microorganisms to mammals, enabling comparative genetic studies.
• CDS1 loss impairs tumorigenic characteristics in nasopharyngeal carcinoma, linking the pathway to cancer.
• Enzyme activity levels regulate phospholipid biosynthetic enzymes, indicating feedback control.
• Relevant to lipid topogenesis and membrane biogenesis research.
• Provides a target for CRISPR-based knockout, point mutation, knock-in, and overexpression studies.
What Happens During CDP-diacylglycerol biosynthetic process?
Substrate activation and CTP coupling
In simple terms: The cell attaches a high-energy carrier (CTP) to a lipid (phosphatidic acid) to make an activated lipid intermediate.
The core reaction of GO:0016024 is catalyzed by CDP-diacylglycerol synthase, which converts phosphatidic acid and CTP into CDP-diacylglycerol and pyrophosphate. This reaction activates the diacylglycerol moiety by forming a glycosidic linkage with cytidine diphosphate, producing the defining product of the pathway. The enzyme is found in microorganisms and mammalian tissues, and its activity is essential for supplying CDP-DAG to downstream lipid biosynthetic routes.
Branchpoint to phosphatidylinositol synthesis
In simple terms: The activated lipid is used to build phosphatidylinositol, a key membrane signaling lipid.
CDP-diacylglycerol is the immediate donor for phosphatidylinositol synthesis at the endoplasmic reticulum, where it reacts with myo-inositol to form phosphatidylinositol. This branch of the pathway links GO:0016024 to phosphoinositide signaling and membrane trafficking. Because phosphatidylinositol is a precursor for multiple signaling lipids, the flux through CDP-DAG synthesis influences diverse cellular processes.
Branchpoint to cardiolipin synthesis in mitochondria
In simple terms: The same activated lipid is also used in mitochondria to make cardiolipin, a lipid important for energy production.
In mitochondria, CDP-diacylglycerol is used for the synthesis of cardiolipin, a signature mitochondrial phospholipid. This mitochondrial branch connects GO:0016024 to oxidative phosphorylation and mitochondrial membrane organization. The dual use of CDP-DAG in endoplasmic reticulum and mitochondria highlights its role as a central lipid intermediate.
Regulation by enzyme activity levels
In simple terms: The amount of the enzyme controls how fast the pathway runs and affects other lipid-making enzymes.
The level of CDP-diacylglycerol synthase activity regulates phospholipid biosynthetic enzymes, indicating that the pathway is subject to feedback control. This regulation helps balance the production of CDP-DAG with downstream demand for phosphatidylinositol and cardiolipin. Consequently, changes in CDS1 or CDS2 expression can alter global phospholipid profiles.
Integration with lipid topogenesis
In simple terms: The pathway is part of how cells decide where different lipids go and how membranes are built.
CDP-DAG synthesis is integrated into lipid topogenesis, the process that determines the distribution of lipids among organelles. Because CDP-DAG is a branchpoint intermediate, its production influences the balance of phospholipids in the endoplasmic reticulum and mitochondria. This integration is essential for membrane biogenesis and organelle identity.
Key Genes Involved in GO:0016024 CDP-diacylglycerol biosynthetic process
The following genes and proteins are experimentally implicated in CDP-diacylglycerol biosynthetic process (GO:0016024) and its downstream branches.
| Gene | Major Role | Research Relevance |
|---|---|---|
| CDS1 | CDP-diacylglycerol synthase 1; catalyzes CDP-DAG synthesis | Loss impairs tumorigenic characteristics in nasopharyngeal carcinoma |
| CDS2 | CDP-diacylglycerol synthase 2; catalyzes CDP-DAG synthesis | Mammalian CDP-DAG synthase isoform studied in lipid metabolism |
| CDS (microbial homologs) | CDP-diacylglycerol synthase in microorganisms | Model enzyme for mechanism and regulation |
| PIS | Phosphatidylinositol synthase; uses CDP-DAG for PI synthesis | Links CDP-DAG to phosphatidylinositol production |
| CLS | Cardiolipin synthase; uses CDP-DAG in mitochondria | Connects CDP-DAG to cardiolipin synthesis |
| CDP-DAG synthase (mammalian) | Mammalian enzyme converting PA + CTP to CDP-DAG | Characterized in mammalian tissues |
| Phospholipid biosynthetic enzymes | Regulated by CDP-DAG synthase activity | Feedback control of lipid synthesis |
| Mitochondrial lipid enzymes | Use CDP-DAG for mitochondrial phospholipids | Mitochondrial membrane biogenesis |
| ER lipid enzymes | Use CDP-DAG for ER phospholipids | ER membrane and signaling lipid production |
| Lipid topogenesis machinery | Distributes lipids among organelles | Membrane biogenesis and organelle identity |
| CDP-DAG branchpoint regulators | Control flux between PI and cardiolipin branches | Lipid homeostasis |
| CDS1 disease models | Tumorigenic lipid metabolism | Cancer lipid metabolism studies |
How Is CDP-diacylglycerol biosynthetic process Regulated?
The CDP-diacylglycerol biosynthetic process is regulated by the level of CDP-diacylglycerol synthase activity, which in turn regulates phospholipid biosynthetic enzymes. This feedback control helps balance CDP-DAG production with downstream demand for phosphatidylinositol and cardiolipin. Because CDP-DAG is a branchpoint intermediate, its regulation influences the distribution of lipids between the endoplasmic reticulum and mitochondria. Changes in CDS1 expression have been shown to modulate lipid metabolism in cancer cells, indicating that disease contexts can alter pathway activity.
CDP-diacylglycerol biosynthetic process and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| CDS1 | Nasopharyngeal carcinoma; tumorigenic lipid metabolism | CDS1 knockout in cancer cell lines |
| CDS2 | Lipid metabolism disorders | CDS2 point mutation or knockout models |
| PIS | Phosphatidylinositol synthesis defects | PIS knockout or knockdown in ER studies |
| CLS | Mitochondrial cardiolipin deficiency | CLS knockout in mitochondrial models |
| CDP-DAG synthase (microbial) | Microbial lipid metabolism | Microbial knockout and complementation |
Cancer and tumorigenic lipid metabolism
Loss of CDS1 impairs the tumorigenic characteristics of nasopharyngeal carcinoma by modulating lipid metabolism, directly linking GO:0016024 to cancer biology. This suggests that CDP-DAG synthesis supports the lipid demands of tumor cells. Targeting CDS1 or related enzymes may therefore have therapeutic potential in cancers with altered lipid metabolism.
Mitochondrial dysfunction and cardiolipin-related pathology
CDP-DAG is a precursor for cardiolipin synthesis in mitochondria, and cardiolipin is essential for mitochondrial membrane integrity and oxidative phosphorylation. Disruption of CDP-DAG supply could therefore affect mitochondrial function and contribute to mitochondrial disease phenotypes. Research on GO:0016024 is relevant to understanding mitochondrial lipid disorders.
Phosphoinositide signaling and membrane trafficking disorders
CDP-DAG is the donor for phosphatidylinositol synthesis at the endoplasmic reticulum, and phosphatidylinositol is a precursor for signaling lipids. Perturbations in CDP-DAG synthesis could alter phosphoinositide signaling and membrane trafficking. This links GO:0016024 to cellular processes relevant to signaling-related diseases.
From CDP-diacylglycerol biosynthetic process-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of CDS1 affect tumorigenicity? | CDS1 knockout in nasopharyngeal carcinoma cells |
| How does CDS2 mutation affect lipid profiles? | CDS2 point mutation knock-in cell lines |
| Can tagged CDS1 reveal subcellular localization? | Tagged knock-in of CDS1 |
| Does overexpression of CDS1 alter phospholipid enzymes? | CDS1 overexpression cell models |
| What is the role of microbial CDS homologs? | Microbial knockout and overexpression |
| How does CDP-DAG supply affect cardiolipin? | CLS knockout or knockdown in mitochondria |
How to Study the CDP-diacylglycerol biosynthetic process Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Lipidomics (LC-MS) | CDP-DAG and phospholipid levels | Profiling pathway activity |
| Enzyme activity assay | CDP-DAG synthase catalytic activity | Characterizing CDS1/CDS2 variants |
| CRISPR knockout screen | Gene requirements for lipid metabolism | Identifying pathway regulators |
| CRISPR knock-in tagging | Protein localization and interactions | Studying CDS1 subcellular distribution |
| RNA-seq | Transcriptional changes in lipid genes | Assessing feedback regulation |
| Proteomics | Protein abundance and interactions | Mapping pathway complexes |
| Fluorescence imaging | Organelle lipid distribution | Visualizing ER and mitochondrial lipids |
| Metabolic labeling | Flux through CDP-DAG branches | Tracing phosphatidylinositol and cardiolipin synthesis |
Lipidomics and mass spectrometry
Mass spectrometry-based lipidomics can quantify CDP-DAG and downstream phospholipids such as phosphatidylinositol and cardiolipin, providing direct readouts of GO:0016024 activity. These methods are used to profile changes in lipid metabolism after genetic perturbation.
Enzyme activity assays
CDP-diacylglycerol synthase activity can be measured in cell lysates or membrane fractions using radiolabeled or fluorescent substrates, as described for microbial and mammalian enzymes. Such assays are used to determine how mutations or expression changes affect catalytic activity.
CRISPR-based genetic screens
CRISPR knockout and knock-in screens can identify genes that modify CDP-DAG synthesis or its downstream branches. These screens are used to discover regulators of lipid metabolism and potential therapeutic targets.
Imaging and subcellular localization
Fluorescent tagging of CDS enzymes and lipid biosensors can reveal where CDP-DAG synthesis occurs within the endoplasmic reticulum and mitochondria. Imaging approaches help connect the pathway to organelle dynamics.
How CRISPR Can Be Used to Study GO:0016024 CDP-diacylglycerol biosynthetic process
Knockout
CRISPR knockout of CDS1 or CDS2 can abolish CDP-DAG synthesis, revealing essential roles in phosphatidylinositol and cardiolipin production. Knockout models are used to test whether loss of the pathway impairs tumorigenicity or mitochondrial function.
Point Mutation
Point mutation knock-in can model disease-associated or catalytically dead variants of CDP-DAG synthase, allowing separation of catalytic and non-catalytic functions. Such models help determine how specific residues affect enzyme activity and lipid profiles.
Knock-in
Tagged knock-in of CDS1 or CDS2 enables visualization and immunoprecipitation of the endogenous enzymes, revealing their subcellular localization and interaction partners. Knock-in reporters can also be used to monitor pathway activity in live cells.
Overexpression
Overexpression of CDS1 or CDS2 increases CDP-DAG synthesis and can alter the activity of phospholipid biosynthetic enzymes, providing a gain-of-function system to study pathway regulation. Overexpression models are useful for testing downstream lipid changes.
How EDITGENE Supports CDP-diacylglycerol biosynthetic process Research
Researchers studying CDP-diacylglycerol biosynthetic process-related genes often need to determine whether a candidate gene is causally involved in lipid metabolism, membrane biogenesis, or disease phenotypes. EDITGENE provides CRISPR-based cell model services to enable these causal experiments.
Contact EDITGENE today to design your custom CRISPR model for CDP-diacylglycerol biosynthetic process research.
Frequently Asked Questions About CDP-diacylglycerol biosynthetic process
What is CDP-diacylglycerol biosynthetic process?
It is the set of reactions that produce CDP-diacylglycerol, a lipid intermediate formed by coupling phosphatidic acid with CTP.
What is the GO ID for CDP-diacylglycerol biosynthetic process?
The GO ID is GO:0016024.
What genes are involved in CDP-diacylglycerol biosynthetic process?
Key genes include CDS1 and CDS2, which encode CDP-diacylglycerol synthases, as well as downstream enzymes like PIS and CLS.
What enzymes catalyze CDP-diacylglycerol synthesis?
CDP-diacylglycerol synthases catalyze the conversion of phosphatidic acid and CTP to CDP-DAG and pyrophosphate.
Where does CDP-diacylglycerol synthesis occur in the cell?
It occurs at the endoplasmic reticulum and mitochondria, where CDP-DAG is used for phosphatidylinositol and cardiolipin synthesis.
How is CDP-diacylglycerol biosynthetic process regulated?
It is regulated by the level of CDP-diacylglycerol synthase activity, which in turn regulates phospholipid biosynthetic enzymes.
What diseases are linked to CDP-diacylglycerol biosynthetic process?
Loss of CDS1 impairs tumorigenic characteristics in nasopharyngeal carcinoma, and the pathway is linked to mitochondrial and phosphoinositide-related biology.
What experimental models are used to study CDP-diacylglycerol synthesis?
CRISPR knockout, point mutation, knock-in, and overexpression cell models are used to dissect gene function.
Why is CDP-diacylglycerol important for lipid metabolism?
It is a branchpoint intermediate used for phosphatidylinositol and cardiolipin synthesis, affecting membrane composition and signaling.
How can I study CDP-diacylglycerol biosynthetic process with CRISPR?
EDITGENE offers knockout, point mutation, knock-in, overexpression, and library screening services to study genes in this pathway.
Conclusion
GO:0016024, CDP-diacylglycerol biosynthetic process, defines the enzymatic route that produces CDP-DAG, a central lipid intermediate for phosphatidylinositol and cardiolipin synthesis. Its conservation, regulation, and links to cancer and mitochondrial biology make it a compelling area for genetic and biochemical research. CRISPR-based cell models provide powerful tools to dissect the causal roles of CDS1, CDS2, and related genes in health and disease.
References
- 1. Horvath SE et al.. 2013. Lipids of mitochondria.. Prog Lipid Res 52(4):590-614 PMID: 24007978
- 2. Dowhan W. 1997. CDP-diacylglycerol synthase of microorganisms.. Biochim Biophys Acta 1348(1-2):157-65 PMID: 9370328
- 3. Wang Y et al.. 2025. Loss of CDS1 impairs the tumorigenic characteristics of nasopharyngeal carcinoma by modulating lipid metabolism.. Cell Adh Migr 19(1):2520629 PMID: 40566856
- 4. Jennings W et al.. 2020. CDP-diacylglycerol, a critical intermediate in lipid metabolism.. Chem Phys Lipids 230:104914 PMID: 32360136
- 5. Chauhan N et al.. 2016. Lipid topogenesis--35years on.. Biochim Biophys Acta 1861(8 Pt B):757-766 PMID: 26946259
- 6. Heacock AM et al.. 1997. CDP-diacylglycerol synthase from mammalian tissues.. Biochim Biophys Acta 1348(1-2):166-72 PMID: 9370329
- 7. Blunsom NJ et al.. 2020. Phosphatidylinositol synthesis at the endoplasmic reticulum.. Biochim Biophys Acta Mol Cell Biol Lipids 1865(1):158471 PMID: 31173893
- 8. Shen H et al.. 1997. Regulation of phospholipid biosynthetic enzymes by the level of CDP-diacylglycerol synthase activity.. J Biol Chem 272(17):11215-20 PMID: 9111022
